Cargando…
Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models
Pancreatic cancer (PC) is anticipated to be second only to lung cancer as the leading cause of cancer-related deaths in the United States by 2030. Surgery remains the only potentially curative treatment for patients with pancreatic ductal adenocarcinoma (PDAC), the most common form of PC. Multiple r...
Autores principales: | Garcia, Patrick L., Miller, Aubrey L., Yoon, Karina J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281668/ https://www.ncbi.nlm.nih.gov/pubmed/32456018 http://dx.doi.org/10.3390/cancers12051327 |
Ejemplares similares
-
Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma
por: Miller, Aubrey L., et al.
Publicado: (2020) -
Generation and application of patient-derived xenograft models in pancreatic cancer research
por: Wang, Cheng-Fang, et al.
Publicado: (2019) -
Generation of orthotopic patient-derived xenograft models for pancreatic cancer using tumor slices
por: Curiel-Garcia, Alvaro, et al.
Publicado: (2022) -
Enhancing efficacy of gemcitabine in pancreatic patient-derived xenograft mouse models
por: Inkoom, Andriana, et al.
Publicado: (2020) -
The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
por: Miller, Aubrey L., et al.
Publicado: (2021)